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Introduction
The established picture of immunological dysfunction in
Multiple Sclerosis (MS) posits a central role for T cells. As
a consequence, the development of disease-modifying
treatments (DMTs) has been targeted at sequestering, lys-
ing or depressing production of T cells. This approach has
been generally successful in reducing relapses and surro-
gate imaging markers of diseases activity, but has not been
so effective in delaying the onset of progressive disease,
and/or disability accumulation. In addition response to
even high efficacy treatments is often not complete and
there remain small groups of non-responders suggesting a
degree of biological diversity. As a result much remains to
be achieved in the field of MS therapeutics.
Conversely the role of B cells has remained relatively
under-explored. However, converging lines of evidence
have suggested a key role in antibody presentation, cyto-
kine production, meningeal inflammation, axonal degen-
eration and grey matter demyelination. In particular, this
latter feature may offer an alternative therapeutic target for
the development of therapies which might expect to have
greater efficacy on later and more progressive forms of
disease. This month’s journal club reviews four papers
addressing the role of B cell treatments in MS.
Ocrelizumab versus interferon beta-1a in relapsing
multiple sclerosis
This paper presents composite data from two clinical trials
(OPERA I and OPERA II), run concurrently in two dif-
ferent site groups. Ocrelizumab, a CD20 inhibitor (and
hence B cell selective inhibitor) was compared with the
current, standard first line therapy for MS, Interferon Beta
1a.
Patients aged 18–55, with 2 relapses within the last
2 years (or one within the last 18 months), EDSS 0–5.5 and
MR imaging supportive of the diagnosis were eligible for
inclusion. Patients with primary progressive disease, prior
B cell treatments or disease duration longer than 10 years
were excluded. Participants were assigned by 1:1 ran-
domisation to 600 mg Ocrelizumab (24 weekly) or 44 mg
of interferon beta weekly. The primary outcome was the
annualised relapse rate (ARR) at 96 weeks. There were a
series of secondary outcomes set hierarchically for signif-
icance testing: worsening disability (EDSS increase by 1.0
or more), total number of T2 lesions, new T2 lesions,
disability improvement by 1.0 on the EDSS, pooled dis-
ability progression from 24 to 96 weeks, number of
hypointense regions on T1 sequences, change in the Mul-
tiple Sclerosis Functional Composite score, percentage
change in brain volume, physical component score on the
SF36 and finally the proportion of patients with no evi-
dence of clinical or imaging disease progression.
1636 patients were randomized; 87.8% of patents on
Ocrelizumab and 79.7% in the interferon group completed
the trial. Patients on Ocrelizumab had a 46% lower ARR in
OPERA I and 47% lower in OPERA II. There was a lower
rate of EDSS progression at 12 weeks (9.1 vs 13.6%) and
pooled disability progression at 96 weeks was lower in the
Ocrelizumab group (6.9 vs 10.5%). The MRI measures also
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showed a lower number of total T2 lesions and new lesions
in the Ocrelizumab group. The majority of new lesions
occurred early in the treatment: new lesions later in treat-
ment were less common. In addition, there were fewer T1
hypo-intense lesions in the Ocrelizumab group.
Comments and conclusion Ocrelizumab has demon-
strated superiority over interferon beta 1a across a range of
relevant clinical and imaging measures and the effects on
disability progression are particularly encouraging. How-
ever, it is worth pointing out that the ARRs are comparable
with a recent observational study of Rituximab, and several
randomised controlled trials. The new lesions appearing
earlier in treatment suggest either a ‘wash out’ effect of
disease activity, or more interestingly a change in
immunomodulation.
Hauser SL et al. (2017) NEJM 376:221–234.
Ocrelizumab versus placebo in primary
progressive multiple sclerosis
There are no trials to date which have shown effect on the
primary outcome in progressive MS. This paper reports a
randomized controlled trial of Ocrelizumab versus placebo
in MS.
Inclusion criteria for the trial were age 18–55, EDSS
3.0–6.5 at screening, disease duration less than 15 years,
and positive oligoclonal bands. Patients who had previ-
ously received B cell therapies, had relapsing disease at
any point, or contraindications to either MRI or steroids
were all excluded. EDSS and MRI images were scored by a
single blinded rater. Participants were randomized on 2:1
ratio to either 600 mg or ocrelizumab every 24 weeks,
continued for a total of 5 infusions, or placebo. The pri-
mary outcome measure was percentage of patients with
disability progression on the EDSS at 12 weeks and sus-
tained for 12 weeks, hierarchical secondary endpoints were
the percentage of patients with disability progression con-
firmed at 24 weeks in a time-to-event analysis, change in
performance on the timed 25-foot walk from baseline to
week 120, change in the total volume of brain lesions on
T2-weighted MRI from baseline to week 120, change in
brain volume from week 24 to week 120 and finally change
in SF36 physical component score.
732 patients were randomised, 488 on ocrelizumab
(82% completed 24 weeks), 244 participants on placebo
(71% completed 24 weeks). Results demonstrated a
reduction in disability progression in favour of ocrelizumab
at 12 weeks (ocrelizumab 32.9 vs 39.3% placebo), which
was sustained at 24 weeks (ocrelizumab 29.6 vs 35.7%
placebo). In addition a greater proportion of patients on
placebo had deterioration in their timed walk. The imaging
data also demonstrated a reduction of lesions in the
ocrelizumab group, an increase in the placebo group (-3.4
vs ?7.4) and a reduction in the rate of brain volume loss in
the ocrelizumab group. Infections, adverse events and
serious adverse events were comparable in both groups,
apart from infusion reactions, which were more common in
the ocrelizumab group (39.9 vs 25.2%). Importantly, the
incidence of neoplasms was higher in patients treated with
ocrelizumab using data from this trail and that of the
Hauser paper outlined above: (0.4/1000 patients years in
ocrelizumab vs 0.2 in comparator groups i.e. MS patients
on alternative treatments).
Comments and conclusions These results are highly
encouraging, and suggest that the first treatment for pri-
mary progressive disease is on the horizon. However,
although the authors point out that the OLYMPUS trial was
negative, it is worth noting that pre-planned subgroup
analyses suggested benefits in some groups. Furthermore,
the outcome measure is rather short compared to trends
seen in large-scale epidemiological work, when longer
periods of follow-up are required. Finally, the neoplasm
rate, albeit small, is a cause for concern and would have to
be discussed with patients starting ocrelizumab.
Montalban X et al. (2017) NEJM 376:209–220.
Rituximab in multiple sclerosis: A retrospective
observational study on safety and efficacy
Previous trials of Rituximab in MS have delivered mixed
results with some evidence of benefit in relapsing disease,
and widespread adoption within some countries. This was
an observational cohort study to assess evidence of benefit
from Rituximab in relapsing-remitting disease.
This retrospective cohort study used a registry drawn
from three hospitals in Sweden, with participants recruited
from 2001. All patients received either 500 or 1000 mg of
Rituximab every 6–12 months and had MR imaging at the
same time. CD19, JCV levels and immunoglobulins were
all routinely recorded, as were adverse events: deaths,
malignancies, autoimmune disorders, and infections.
The study included 557 patients with relapsing-remitting
disease, 198 with secondary progressive disease and 67
with primary progressive disease; 20% of patients received
rituximab first line and the remainder following first line
treatment with either interferon or natalizumab. Mean
follow-up was 23.1 months. ARR were very low: 0.044 for
relapsing-remitting disease, 0.038 for secondary progres-
sive disease and 0.015 for primary progressive disease.
EDSS remained unchanged for patients with relapsing
disease, and showed small, non-significant increases in
progressive disease. Analysis of imaging data revealed that
new contrast enhancing lesions were visible in only 4.6%
and that new lesions were common in the first 6 months of
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treatment. Infections and infusions were the most common
adverse events, three patients developed malignancies and
there were four deaths.
Comments and conclusion The ARR in this cohort were
very low, suggesting a significant effect on the inflamma-
tory component of disease. Although by their nature ret-
rospective cohort studies are at risk of selection bias, in this
case the cohort was mainly composed of patients who had
failed first line therapy, and therefore, might be considered
to have a more severe disease phenotype. In addition as
seen in the ocrelizumab trials new lesions were most
commonly seen shortly after treatment induction.
Salzer J et al. (2016) Neurology 87:2074–2081.
Severe B-cell-mediated CNS disease secondary
to alemtuzumab therapy
This paper describes the unusual clinical course of two
patients with MS who were treated with alemtuzumab; an
anti CD52 therapy; considered a high efficacy treatment
which causes peripheral lymphocyte ablation via comple-
ment mediated lysis. Subsequent immune reconstitution
then occurs which is thought to be beneficial for MS with
specific cell types repopulating after different intervals. B
cells re-constitute earliest over several months with more
significant delay for CD4? and CD8? subsets.
The first case, a 41 year old male received alemtuzumab
for severe relapsing disease. Five months following first
infusion he re-presented with symptoms consistent with
diffuse disease relapse: apraxia, dysarthria, cognitive
impairment and an asymmetrical tetraparesis. An MR brain
demonstrated multiple supratentorial ring enhancing
lesions. A change of treatment to Rituximab then appeared
to stabilise the disease. The second case (a 25-year-old
female) presented with left sided ataxia and numbness
9 months following alemtuzumab treatment. An MR brain
revealed multiple ring enhancing lesions and once again
she responded well to Rituximab.
Comments and conclusion Lack of response to alem-
tuzumab is unusual and in particular the very high levels of
clinical and radiological disease activity post-treatment
seen in these cases. It does seem likely that the aetiology of
deterioration in both cases was an exacerbation of pre-
existing neuro-inflammatory disease given the response to
immunosuppression. The importance of this report is to
lend further support to the concept of biological diversity in
MS and that a subset of patients may have B cell driven
disease that may be more resistant to T cell targeted ther-
apies which may even have the effect of exacerbating
ongoing inflammatory activity.
Haghikia A et al. (2017) Lancet Neurology 16:104–106.
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